13 completed. 13 Phase 3.
By phase and status
Follow RTV: new trials by email Literature Review of RTV trials Research Report on RTV
Trials (filtered) newest first · largest first
All 13 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a Lonafarnib, Ritonavir, PEG IFN-alfa-2a - Hepatitis Delta Virus | Phase 3 | Completed | 407 | 2018-12-01 | 2023-04-14 |
Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women E/C/F/TAF, E/C/F/TDF, ATV - HIV-1 Infection | Phase 3 | Completed | 472 | 2016-02-19 | 2020-03-04 |
Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults RTV, ATV, DRV - HIV-1 Infection | Phase 3 | Completed | 578 | 2015-11-20 | 2020-12-29 |
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF - HIV, HIV Infections | Phase 3 | Completed | 1443 | 2013-03-27 | 2021-04-13 |
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women E/C/F/TDF, ATV, RTV - Acquired Immunodeficiency Syndrome, HIV Infections | Phase 3 | Completed | 583 | 2012-10-24 | 2019-09-20 |
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients PI, RTV, FTC/TDF - Acquired Immunodeficiency Syndrome, HIV Infections | Phase 3 | Completed | 438 | 2011-11-01 | 2016-06-08 |
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF FTC/RPV/TDF, PI, RTV - HIV-1 Infection | Phase 3 | Completed | 482 | 2010-11-01 | 2015-12-04 |
Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults COBI, RTV, ATV - HIV, HIV Infections | Phase 3 | Completed | 698 | 2010-04-01 | 2016-05-23 |
Comparative Study of Three NNRTI-Sparing HAART Regimens Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Darunavir - HIV Infection | Phase 3 | Completed | 1814 | 2009-05-01 | 2014-09-05 |
A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN) Darunavir (DRV), Ritonavir (rtv) - Human Immunodeficiency Virus - Type 1 | Phase 3 | Completed | 590 | 2007-10-01 | 2013-02-15 |
BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet - HIV Infections | Phase 3 | Completed | 1057 | 2005-11-01 | 2011-05-09 |
Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults Abacavir/Lamivudine, Atazanavir, Efavirenz - HIV Infections | Phase 3 | Completed | 1864 | 2005-09-01 | 2018-10-12 |
A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection Indinavir sulfate, Ritonavir, Abacavir sulfate - HIV Infections | Phase 3 | Completed | 165 | | 2013-09-06 |
Conditions studied
HIV Infections (8) · Acquired Immunodeficiency Syndrome (3) · Hepatitis D (1)
Sponsors
Gilead Sciences (7) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (2) · Bristol-Myers Squibb (1) · Eiger BioPharmaceuticals (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Tibotec Pharmaceuticals, Ireland (1)
Countries
United States (12) · Puerto Rico (11) · France (9) · United Kingdom (9) · Belgium (8) · Canada (8) · Germany (8) · Italy (8) · Spain (8) · Austria (6) · Dominican Republic (6) · Thailand (6) · Australia (5) · Portugal (5) · Brazil (4)
Top investigators
Brian Conway (1) · Eric Daar, MD (1) · Huyen Cao, MD (1) · Igho Ofotokun, MD (1) · Jeffrey L. Lennox, MD (1) · John Flaherty, PharmD (1) · Judith Silverstein Currier, MD, MSc (1) · Paul Sax, MD (1) · Rafick-Pierre Sekaly (1) · Raphael Landovitz, MD, MSc (1) · Thai Nguyen-Cleary (1)
Results publications
PMID 33901188, PMID 36912172, PMID 19952143, PMID 21148235, PMID 21320923, PMID 21606537, PMID 21690627, PMID 21732894, PMID 22121190, PMID 23148287, PMID 23204164, PMID 23532097, PMID 23558157, PMID 24253247, PMID 24384588, PMID 24637543, PMID 24872136, PMID 24908550, PMID 24908551, PMID 24979445, PMID 25285539, PMID 25767256, PMID 25904376, PMID 26009829, PMID 26181707, PMID 26286337, PMID 26538525, PMID 26797215, PMID 27562742, PMID 27774892, PMID 28259777, PMID 28555519, PMID 29368537, PMID 29925490, PMID 30642925, PMID 30932951, PMID 31303140, PMID 31430369, PMID 31609930, PMID 31826005, PMID 32829410, PMID 33870433, PMID 35179037, PMID 37407002, PMID 38160309
NIH funding
U01AI068636 (2), 2009 (1), 2015 (1)